| Previous Close | 12.43 |
| Open | 12.32 |
| Bid | 12.23 x 1000 |
| Ask | 12.47 x 1000 |
| Day's Range | 12.18 - 12.61 |
| 52 Week Range | 8.60 - 25.50 |
| Volume | 17,496 |
| Avg. Volume | 59,988 |
| Market Cap | 209.093M |
| Beta (3Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.22 |
| Earnings Date | Mar 12, 2018 - Mar 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced the completion of its rights offering, which expired at 5:00 p.m. Eastern Time on December 6, 2018 (the “Expiration Date”). In accordance with the pricing structure of the rights offering described in the prospectus relating to the offering, Pulse Biosciences has determined that the final subscription price per share for the shares offered in the rights offering is $12.5658 per share, which is the volume weighted average price of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.
Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has commenced its previously announced rights offering of $45,000,000 of its common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m. Eastern Time on Thursday December 6, 2018 (the “Expiration Date”). Pursuant to the rights offering, Pulse Biosciences is distributing, at no charge to the holders of its common stock, non-transferable subscription rights to purchase up to $45,000,000 of shares of its common stock at a subscription price per share equal to the lesser of (i) $13.33 per share (the “Initial Price”) or (ii) the volume weighted average price (the “Alternate Price”) of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.
Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on November 15, 2018.
Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has set key dates and pricing structure for its previously announced rights offering of $45,000,000 of its common stock. Pulse Biosciences intends to issue non-transferable subscription rights to purchase shares of its common stock to common stockholders as of 5:00 p.m. Eastern Time on Monday November 19, 2018 (the “Record Date”).
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT
Pulse Biosciences, Inc. (PLSE) (the “Company”, or “Pulse Biosciences”) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001 per share, at a subscription price to be determined. Assuming the rights offering is fully subscribed, the Company will receive gross proceeds of approximately $45 million, less expenses of the rights offering.
Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, today announced that the Company will report third quarter 2018 operational highlights and financial results on Tuesday, October 30, 2018.
Pulse Biosciences, Inc. (PLSE), a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 20,750 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on October 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Fourth Dermatology Study Will Evaluate Nano-Pulse Stimulation™ in Treating Cutaneous Warts
Anyone researching Pulse Biosciences Inc (NASDAQ:PLSE) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...
Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary Nano-Pulse Stimulation™ platform, announced today that Darrin Uecker, President and Chief Executive Officer, is scheduled to present at the Cantor Global Healthcare Conference in New York at 4:00 p.m.
Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse StimulationTM (NPSTM) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 34,250 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 17, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.
Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 18,250 shares of Pulse Biosciences common stock to five new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on August 3, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Pulse Biosciences, Inc. (NASDAQ: PLSE ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern Time. ...
Pulse Biosciences, Inc. (PLSE) today announced the treatment of the first patient in a clinical study to evaluate Nano-Pulse Stimulation (NPS) in a common skin cancer, Basal Cell Carcinoma (BCC). Patients in the study will be treated with NPS prior to resection of the BCC lesion, which is the standard of care for BCC lesions. Post resection tissue samples will be assessed for elimination of the BCC lesion in the NPS treatment zone and for biomarkers indicating an immune response to the NPS-treated BCC lesions.
Pulse Biosciences, Inc. , a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation platform, today announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018.
Pulse Biosciences, Inc. (PLSE) today announced treatment of the first patients in its multicenter study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH), an unsightly benign skin lesion that typically appears on facial skin and is considered a difficult-to-treat condition with current modalities. NPS is a non-thermal technology that utilizes ultra-short, nanosecond pulsed electrical fields to directly affect cell membranes and intracellular structures while sparing non-cellular tissues.
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Pulse Biosciences, Inc. breached their fiduciary duties to shareholders.
Pulse Biosciences, Inc. (PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 30,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on June 22, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
RADNOR, PA / ACCESSWIRE / June 20, 2018 / Kaskela Law LLC is investigating Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) on behalf of the Company's stockholders. ...
Pulse Biosciences, Inc. (PLSE) (the “Company” or “Pulse Biosciences”), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the Company’s Board of Directors (the “Board”) granted non-qualified stock options covering an aggregate of 102,000 shares of Pulse Biosciences common stock to three new employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on May 15, 2018. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual's entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).